A pilot study of durvalumab and tremelimumab and immunogenomic dynamics in metastatic breast cancer

Immune checkpoint inhibitors produce modest responses in metastatic breast cancer, however, combination approaches may improve responses. A single arm pilot study was designed to determine the overall response rate (ORR) of durvalumab and tremelimumab, and evaluate immunogenomic dynamics in metastat...

Descripción completa

Detalles Bibliográficos
Autores principales: Santa-Maria, Cesar August, Kato, Taigo, Park, Jae-Hyun, Kiyotani, Kazuma, Rademaker, Alfred, Shah, Ami N., Gross, Leeaht, Blanco, Luis Z., Jain, Sarika, Flaum, Lisa, Tellez, Claudia, Stein, Regina, Uthe, Regina, Gradishar, William J., Cristofanilli, Massimo, Nakamura, Yusuke, Giles, Francis J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5922371/
https://www.ncbi.nlm.nih.gov/pubmed/29721177
http://dx.doi.org/10.18632/oncotarget.24867

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5922371/
https://www.ncbi.nlm.nih.gov/pubmed/29721177
http://dx.doi.org/10.18632/oncotarget.24867

Ejemplares similares